



PRESS RELEASE

GENFIT: OUTCOME OF THE ORDINARY AND EXTRAORDINARY SHAREHOLDERS' MEETING OF JUNE 16, 2017

- › **Approval of the change in mode of administration and management of the Company**
- › **Nomination of the Chairman and CEO and the members of the Board committees**

Lille (France), Cambridge (Massachusetts, United States), June 16, 2017 – GENFIT (Euronext: GNFT - ISIN: FR0004163111), a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announced the results of the Ordinary and Extraordinary Shareholders' Meeting which took place on June 16, 2017, in Lille, France.

All of the resolutions of the Shareholders' Meeting were voted in accordance with the Executive Board's recommendations.

The Ordinary and Extraordinary Shareholders' Meeting was held with a total of 7,830,841 shares participating out of a total of 31,162,150 shares with voting rights, representing a quorum of 25.12%.

Details of votes will be available shortly on the Company's website, in the documentation center (<http://www.genfit.com/investors/documentation-center/>).

In particular, the shareholders approved the change in mode of administration and management of the Company and nominated all of the new members of the Board of Directors.

The new Board of Directors met following the Ordinary and Extraordinary Shareholders' Meeting and appointed Mr. Jean-François MOUNEY as Chairman of the Board of Directors and Chief Executive Officer of the Company. Mr. Xavier GUILLE DES BUTTES was appointed Vice-Chairman of the Board of Directors.

The new Board of Directors is now composed of the following members:

- Jean-François Mouney, Chairman
- Xavier Guille des Buttes, Vice-Chairman
- Anne-Hélène Monsellato
- Catherine Larue
- Frédéric Desdouits
- Philippe Moons
- Biotech Avenir, represented by Florence Séjourné



PRESS RELEASE

The members of the Audit Committee and the Nominations and Compensation Committee were also appointed:

Audit Committee :

- Anne-Hélène Monsellato, President
- Philippe Moons
- Xavier Guille des Buttes

Nominations and Compensation Committee :

- Xavier Guille des Buttes, President
- Jean-François Mouney
- Catherine Larue

Jean-François Mouney, Chairman & CEO of GENFIT, commented:

“On behalf of the Board of Directors of GENFIT, I express my warmest thanks to our shareholders for their overwhelming support of the change in mode of administration and management of the Company and their approval of the tools necessary for the Company’s development and pursuit of its strategy. I would also like to thank the new Board of Directors for its support and am pleased to accompany GENFIT as its Chairman of the Board of Directors and Chief Executive Officer in the next stage of its life. This Board of Directors, made up of a number of highly-skilled experts, will be more involved in the strategy of the Company and provide real support for the development and growth of GENFIT in the years to come.”

ABOUT GENFIT

GENFIT is a biopharmaceutical company focused on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatment and an increasing number of patients worldwide. GENFIT’s R&D efforts are focused on bringing new medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver (such as NASH – Nonalcoholic steatohepatitis) and more generally the gastrointestinal arena. GENFIT’s approach combines novel treatments and biomarkers. Its lead proprietary compound, elafibranor, is currently in a Phase 3 study. With facilities in Lille and Paris, France, and Cambridge, MA (USA), the Company has approximately 130 employees. GENFIT is a public company listed in compartment B of Euronext’s regulated market in Paris (Euronext: GNFT - ISIN: FR0004163111). www.genfit.com

FORWARD LOOKING STATEMENT / DISCLAIMER

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from



PRESS RELEASE

those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, including related to biomarkers, progression of, and results of clinical data from, the RESOLVE-IT trial, review and approvals by regulatory authorities, such as the FDA or the EMA, regarding in particular, elafibranor in NASH and PBC, as well as other indications, and biomarkers, the success of any inlicensing strategies, the Company's continued ability to raise capital to fund its development, as well as those discussed or identified in the Company's public filings with the AMF, including those listed under Section 4 "Main Risks and Uncertainties" of the Company's 2016 Registration Document registered with the French Autorité des marchés financiers on April 28, 2017 under n° R.17-034, which is available on GENFIT's website (www.genfit.com) and on the website of the AMF (www.amf-france.org). Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in GENFIT in any country. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.

CONTACT

GENFIT | Jean-François Mouney – Chairman & CEO | +333 2016 4000

MILESTONES – Press Relations | Bruno Arabian | +331 8362 3484 / +336 8788 4726 – barabian@milestones.fr